| Identification | Back Directory | [Name]
lurasidone | [CAS]
367514-87-2 | [Synonyms]
urasidone
lurasidone
Lurasidone Base
Lurasidone, >=98%
Lurasidone (SM13496)
(3aR,4S,7R,7aS)-2-((1R,2R)-2-(4-(1,2-Benzothiazol-3-yl)piperazin-1-ylmethyl)cyclohexylmethyl)hexahydro-4,7-methano-2H-isoindole-1,3-dione
(3aR,4S,7R,7aS)-2-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]Methyl}cyclohexyl]Methyl}hexahydro-1H-4,7-Methanoisoindole-1,3(2H)-dione
(3aR,4S,7R,7aS)-2-[[(1R,2R)-2-[[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]methyl]cyclohexyl]methyl]hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione
4-{[(1R,2R)-2-{[4-(2$l^{4}-thia-6-azatricyclo[5.4.0.0^{2,6}]undeca-1(11),2,4,7,9-pentaen-5-yl)piperazin-1-yl]Methyl}cyclohexyl]Methyl}-4-azatricyclo[5.2.1.0^{2,6}]deca-1(9),2(6),7-triene-3,5-dione | [EINECS(EC#)]
696-042-8 | [Molecular Formula]
C28H36N4O2S | [MDL Number]
MFCD14635357 | [MOL File]
367514-87-2.mol | [Molecular Weight]
492.68 |
| Chemical Properties | Back Directory | [Melting point ]
146-149°C | [Boiling point ]
623.4±55.0 °C(Predicted) | [density ]
1.273 | [storage temp. ]
-20°C Freezer | [solubility ]
Chloroform (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
8.41±0.50(Predicted) | [color ]
White to Off-White | [InChIKey]
PQXKDMSYBGKCJA-CVTJIBDQSA-N | [SMILES]
C1(=O)[C@]2([H])[C@@]([H])([C@]3([H])C[C@@]2([H])CC3)C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(C2C3=C(SN=2)C=CC=C3)CC1 | [CAS DataBase Reference]
367514-87-2 |
| Hazard Information | Back Directory | [Definition]
ChEBI: An N-arylpiperazine that is (3aR,4S,7R,7aS)-2-{[(1R,2R)-2-(piperazin-1-ylmethyl)cyclohexyl]methyl}hexahydro-1H-4,7-m
thanoisoindole-1,3(2H)-dione in which position N4 of the piperazine ring is substituted by a 1,2-benzothiazol-3-yl group. Lurasidone is used (generally as the hydrochloride salt) as an atypical antipsychotic for the treatment of schizoph
enia. | [Description]
The atypical antipsychotic lurasidone (also known as SM-13496) was
approved in the United States in 2010 as an oral agent for the treatment
of patients with schizophrenia. Lurasidone has potent affinity for D2 (Ki= 1.7 nM)
and 5-HT2A (Ki= 2.0 nM) receptors and acts as an antagonist at both
receptors. It is also a partial agonist at the 5-HT1A receptor and,
unlike other atypical agents, is a potent antagonist at the 5-HT7 receptor;
both of these activities are thought to confer beneficial cognitive properties.
Lurasidone is further differentiated by its lack of affinity for muscarinic
and histamine H1 receptors and its weak affinity for the 5-HT2C
receptor. Antagonism at H1 and 5-HT2C receptors has been implicated in
weight gain associated with atypical agents, while muscarinic receptor
antagonism is associated with cognitive deficits. | [Originator]
Dainippon Sumitomo Pharma (Japan) | [Uses]
Lurasidone is a benzisothiazole derivative (C28H36N4O2S·HCl, MW 529.14) and second-generation atypical antipsychotic that functions as a complete antagonist at dopamine D2 and serotonin 5-HT2A receptors[1][2][3]. Approved by the FDA in 2010 for schizophrenia in adults and later for major depressive episodes associated with bipolar I disorder, lurasidone reduces positive and negative symptoms, anxiety, depression, and suicidal ideation[1][2][4]. Clinical studies support its efficacy and safety in short- and long-term treatment, with a favorable metabolic profile characterized by lower propensity for weight gain and minimal impact on glucose, lipids, and QTc interval[2][4]. The recommended starting dose for schizophrenia is 37 mg/day, administered once daily with a meal to ensure adequate absorption[2][4]. | [Brand name]
Latuda | [storage]
Store at -20°C | [References]
[1]
Ekinci, R., eyma Uygun. (2025). Mechanism of Action and Uses of Lurasidone, A New Generation of Antipsychotics: A Review. Psychiatry and Behavioral Sciences, 15(1), 25. https://doi.org/10.5455/pbs.20241104052122
[2]
Javed, A., Arthur, H., Curtis, L., Hansen, L., Pappa, S. (2019). Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. Neurology and Therapy, 8(2), 215–230. https://doi.org/10.1007/s40120-019-0138-z
[3]
Ricci, V., Berardis, D. D., Maina, G. (2024). Third-Generation Antipsychotics and Lurasidone in the Treatment of Substance-Induced Psychoses: A Narrative Review. Healthcare, 12(3), 339. https://doi.org/10.3390/healthcare12030339
[4]
Mora, F., Sánchez-Lafuente, C. G., Iceta, M. D., Roset, C., Cárdenas, A., Pérez, D., Álvarez-Barón, E., Gabarda-Inat, I., Group, S. R. (2025). Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence. Frontiers in Psychiatry, 15. https://doi.org/10.3389/fpsyt.2024.1506142 |
| Questions And Answer | Back Directory | [Drug for the treatment of schizophrenia]
Lurasidone is developed by Japan's Dainippon Sumitomo Pharma which is an atypical antipsychotic,and is a classification of drug registration 3.1 class, it is suitable for the treatment of patients with schizophrenia. Its efficacy is Determined in four six weeks in adult patients with schizophrenia controlled studies. The exact mechanism of the treatment of schizophrenia, like other atypical antipsychotics ,is not very clear,and may be related to the antagonism of the dopamine D2 and serotonin 2A (5-HT2A) receptors. For the treatment of schizophrenia, a study has reported lurasidone can improve cognitive function.
October 28, 2010 ,the FDA approved lurasidone hydrochloride (lurasidone HCI) tablets once a day for the first-line treatment of patients with schizophrenia, the trade name is Latuda.
Dosage: The recommended starting dose is 40 mg/d, the effective dose range is 40~120 mg /· d, the maximum recommended dose is 80 mg /· d. It should be taken with food.
Adverse reaction: common adverse reactions are somnolence, akathisia, nausea, Parkinson's disease-like symptoms and emotional anxiety. Lurasidone has no physical dependence, less likely to cause weight gain, it does not cause glucose, lipids (lipids), it changs the period between ECG and QT.
The above information is edited by the Chemicalbook of Tian Ye.
|
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
Eastbang Pharmaceuticals Technology Co., Ltd.
|
| Telephone: |
+86 (20) 28996708,29078958,28139708,29076128,28133708,28139728,28139738,28133718,021-31663278,021-31663578,021-60538387 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList13633/0_EN.htm |
|